Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of imatinib mesylate in reducing
cutaneous thickening and tethering in patients with nephrogenic systemic fibrosis (NSF). The
study will also work to assess the safety and tolerability of imatinib mesylate in patients
with chronic kidney disease and NSF.